CD73: agent development potential and its application in diabetes and atherosclerosis.

Area of Science:

• Biochemistry
• Immunology
• Molecular Biology

Background:

• CD73 catalyzes adenosine monophosphate (AMP) to adenosine (ADO), impacting inflammation and immune responses.
• CD73 exhibits context-dependent roles, acting protectively in diabetes but pro-atherosclerotically with age.
• The dual nature of CD73 necessitates a nuanced understanding for therapeutic development.

Purpose of the Study:

• To review the current knowledge of CD73's role in diabetes and atherosclerosis.
• To explore the potential of CD73-targeting agents for therapeutic development.
• To highlight emerging targets like circNT5E for modulating CD73 expression.

Main Methods:

• Literature review of studies on CD73 function in metabolic and vascular diseases.
• Analysis of agents that upregulate or downregulate CD73 activity.
• Examination of clinical trial data for CD73-modulating therapies.
• Investigation of non-coding RNAs, such as circNT5E, associated with CD73.

Main Results:

• Upregulation of CD73 by various agents showed promise in decreasing diabetes and atherosclerosis.
• Downregulation of CD73 also demonstrated efficacy in reducing atherosclerosis.
• While many CD73 agents are in trials, none are approved for diabetes or atherosclerosis; most are inhibitors.
• circNT5E was identified as a promoter of CD73 expression, suggesting it as a potential therapeutic target.

Conclusions:

• CD73 presents a complex but promising target for managing diabetes and atherosclerosis.
• Further research into CD73 modulation and novel targets like circNT5E is warranted for effective agent development.
• The development of CD73-specific therapies requires careful consideration of its dual roles and potential side effects.